Enforcement Report - Week of February 28, 2024
Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits
Specialty pharma company Assertio paying $9 million upfront for exclusive rights to the Sympazan oral film formulation.
WARREN, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today a transaction to license Sympazan® (clobazam) oral film to Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients. Sympazan (clobazam) oral film is for the adjunctive treatment of seizures associated with Lennox?Gastaut Syndrome (LGS) in patients aged two years of age or older.
Accord's Generic Clobazam Receives Approval in the U.S.
Aurobindo Pharma ’s Generics Clobazam Receives Approvals In US
Enforcement Report - Week of January 26, 2022
The Indian Pharmacopoeia Commission (IPC), which is the National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI) has flagged drug safety alerts revealing that drugs-- Clobazam, Baclofen and Rosuvastatin and Ticagrelor interactions are associated with risks like DRESS Syndrome, encephalopathy and rhabdomyolysis respectively.
Alkem Labs`s Generic Lacosamide Receives Approval In US
Aquestive Therapeutics is still reeling from a precipitous drop in its stock price after the FDA rejected its oral film for seizure control.